The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 19 rounds in the feed, most often at Series B and in Biotech.
Venture capitalinvus.comRounds from 2021-07-27 to ~ 2026-10-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Soufflé Therapeutics A leading RNA therapies company aimed at advancing the next generation of therapies designed to help people live healthier lives | Series B Verified against 1 of 29 sources | $135M | ~ 2026-10-10 | [ PART ] |
Precision Neuroscience A brain–computer interface (BCI) technology company | Series D |
| $250M |
| 2026-09-11 |
| [ PART ] |
Encoded Therapeutics Encoded Therapeutics develops gene therapies targeting genetic disorders, primarily focusing on neurological conditions. | Series F Verified against 4 of 7 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $275M | 2026-09-09 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series E Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $188M | 2026-08-06 | [ PART ] |
Flare Therapeutics A biotech startup targeting transcription factors | Series C Verified against 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $85M | 2026-06-30 | [ PART ] |
Ray Therapeutics Optogenetic therapies designed to restore functional vision for people with degenerative retinal diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-04-21 | [ PART ] |
CORXEL Pharmaceuticals Innovative therapies for cardiometabolic diseases, targeting conditions such as obesity and Type 2 Diabetes Mellitus. | Series D+ Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $287M | 2026-01-22 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2026-01-12 | [ PART ] |
SanegeneBio Innovative RNAi therapeutics for chronic diseases, targeting autoimmune, cardiovascular, obesity, and metabolic diseases for healthcare providers and researchers. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-12-08 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-12-03 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-17 | [ PART ] |
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $157M | 2025-10-27 | [ PART ] |
Veradermics Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-10-16 | [ PART ] |
Kailera Therapeutics Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity | Series B Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $600M | 2025-10-14 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ PART ] |
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2023-02-21 | [ PART ] |
LifeMine LifeMine is a clinical-stage biopharmaceutical company that develops next-generation precision medicines through an innovative drug discovery approach focused on evolutionary insights from fungi, targeting patients in need of breakthrough therapies. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2022-03-23 | [ PART ] |
Jumbotail A B2B marketplace connecting grocery retailers with brands and staples producers in India. | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $85M | 2021-12-20 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |